Skip to main content
Fig. 9 | BMC Biotechnology

Fig. 9

From: Optimization of expression, purification and secretion of functional recombinant human growth hormone in Escherichia coli using modified staphylococcal protein a signal peptide

Fig. 9

Panel A: Western blot analysis of protein samples extracted from cytoplasm (columns 2 and 3), periplasm (column 4), and culture medium (column 5). Column 1 is the standard processed form of hGH (a commercially available hGH from Novo Nordisk company which was used as a positive control). Panel B: Western blot analysis of different protein fractions obtained after expression of hGH from recombinant E. coli. The lanes are loaded as follows: lane 1, cytoplasmic fraction, lane 2, protein extracted from cytoplasm before induction as a negative control; lane 3 is a molecular weight protein marker; lane 4, a commercially available hGH from Novo Nordisk company which was used as a positive control and lane 5 is the periplasmic fraction of hGH obtained by osmotic shock preparation. Both panels (panel A and panel B) were run at the same time and only in the gel displayed in panel B protein marker was loaded which can be easily detect the hGH bands. In addition, in both panels (lane 1 the panel A and lane 4 in panel B), are a commercial product of the hGH from Novo Nordisk company which was used as a control, which can also be considered as a marker. This standard hGH has the same mobility on the gel as our processed form of the recombinant

Back to article page